A comprehensive review on analytical validation methods of cenobamate and upadacitinib

Abstract

A new antiepileptic medication called cenobamate was just licenced to treat adult partial-onset seizures. By specifically focusing on the persistent sodium current, its special method of action lowers neuronal excitability and the spread of seizures. Cenobamate has been shown to be safe and effective in clinical trials, resulting in notable decreases in the frequency of seizures and enhancements in the patient's quality of life. Patients with uncontrollably occurring seizures may find it to be a desirable option due to its excellent pharmacokinetic profile and few medication interactions. This study examines the possible advantages and disadvantages of cenobamate use in the treatment of epilepsy and summarises the available data in favour of it. A Janus kinase (JAK) inhibitor called The medication upadacitinib is authorised Regarding the management of moderate- to-severe adult inflammatory arthritis (RA). Upadacitinib reduces inflammation and joint injury by inhibiting pro-inflammatory cytokine signalling by blocking JAK enzymes. Its side effects are tolerable and its safety profile is typically acceptable. This review looks at the data that is currently available to support the use of Upadacitinib in the therapy of RA, emphasising its safety, effectiveness, and potential as a treatment alternative for patients who don't respond well to traditional medications.